T-Therapeutics

Biotech · Oncology · Immunology

Funding

T-Therapeutics raises $133M Series B for bispecific cancer, autoimmune drugs

Four of the world's largest drugmakers are betting on a platform that claims access to intracellular targets no antibody can reach.

• T-Therapeutics closed an oversubscribed $133M (£100M) Series B co-led by Advent Life Sciences and British Business Bank to fund clinical development of two bispecific drug candidates.
• The Cambridge, UK biotech, founded in 2022 as a University of Cambridge spinout, builds T-cell receptor (TCR) bispecific drugs on its OpTiMus platform, which generates fully human TCRs to reach targets long considered undruggable.
• Its lead programs are TTX-008, a preclinical pan-tumor bispecific for solid cancers, and TTX-018, a discovery-stage autoimmune therapy that selectively depletes disease-driving immune cells; neither has entered human trials.
• TCR-based bispecifics can recognize protein fragments inside cells, opening roughly 20 times more drug targets than conventional antibody therapies, according to T-Therapeutics' chief scientific officer.
• The round follows a $91 million extended Series A completed about a year earlier, as the company shifts from discovery research toward clinical-stage development.
• Backing from the venture arms of Lilly, J&J, Sanofi and Merck KGaA signals growing big-pharma appetite for TCR-based bispecifics, a modality seen as a path to finally targeting solid tumors that have resisted other T-cell engager approaches.